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decreased from 139 to 137 mmol/l on day 2, and then
increased to 140 mmol/l on day 7. This slow increase in
serum Na concentration did not cause central pontine
myelinolysis.
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About the association between
high alkaline phosphatase
and risk of death and
hospitalization in dialysis
patients
Kidney International (2009) 75, 1114; doi:10.1038/ki.2008.673
To the Editor: We have been very interested by the
epidemiological link between high alkaline phosphatase and
the risk of death and hospitalization in the Dialysis Outcomes
and Practice Patterns Study cohort.1 It is interesting that the
authors pointed out that this association was independent of
calcium, phosphorus, and parathyroid hormone levels, as
well as active vitamin D use. However, no mention was made
about their 25 OH vitamin D serum levels, which may vary
widely according to country latitude, as well as country-
specific reimbursement policy, for intravenous or oral
administration of active or plain vitamin D.
Knowledge of 25 OH vitamin D status is important, as
Wolf et al.2 have pointed out that low 25 OH vitamin D in
incident hemodialysis patients was a strong predictor of early
all-cause mortality.
1. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline
phosphatase levels in hemodialysis patients are associated
with higher risk of hospitalization and death. Kidney Int 2008; 74:
655–663.
2. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early
mortality among incident hemodialysis patients. Kidney Int 2007; 72:
1004–1013.
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Response to ‘About the
association between high alkaline
phosphatase and risk of death
and hospitalization in dialysis
patients’
Kidney International (2009) 75, 1114; doi:10.1038/ki.2008.678
Regarding our article on the Dialysis Outcomes and
Practice Patterns Study (DOPPS),1 the comments by
Baakrim, Shahapuni, Rouached, and Fournier on mortality
risk by serum levels of 25 OH vitamin D2 provide an
important perspective to the dialysis practice. In DOPPS 4,
we inquired about the practice of measuring 25 OH
vitamin D in the sample of international dialysis facilities.
Unfortunately, only 16% of dialysis facility medical
directors indicated that it is being measured routinely
(7% quarterly, 6% biannually, and 3% annually). Any
measurement varied markedly by country, ranging from
0% in the sample of facilities in Australia, New Zealand,
Canada, Sweden, and the United Kingdom to 54% of
facilities in Belgium, 60% in France, and 67% in Germany.
Thus, their comment points to a current area of limited
attention and an opportunity to study the effect of targeted
treatment based on prospective measurement of 25 OH
vitamin D.
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Factors aside from Helicobacter
pylori play an important role in
the occurrence of peptic ulcer
in dialysis patients
Kidney International (2009) 75, 1114–1115; doi:10.1038/ki.2009.26
To the Editor: We read with interest the article entitled
‘Prevalence of Helicobacter pylori in long-term hemodialysis
patients’ by Sugimoto et al.1 In this study, Sugimoto et al.
reported that compared to patients with normal renal
function, the dialysis patients had lower prevalence of
H. pylori, which significantly decreased as the duration of
dialysis increased, and they still had significant peptic ulcer
disease.1 In a 5-year follow-up study of a community
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screening for H. pylori, Hansen et al.2 reported that H. pylori
eradication resulted in a decreased ulcer incidence. Such
effect of decrease of prevalence of H. pylori and, therefore,
decrease of incidence of peptic ulcer between dialysis and
non-dialysis groups seems discrepant.1,2 We believe that
factors aside from H. pylori play an important role in the
occurrence of peptic ulcer in dialysis patients. In our 2-year
follow-up study after H. pylori eradication, we found that
peptic ulcer recurred more in dialysis patients than in non-
dialysis patients, with intention to treat analysis (8/32, 25 vs
2/64, 3.1%, P¼ 0.001, OR: 10.000, 95% CI: 1.979–50.540) or
per protocol analysis (8/29, 27.5 vs 2/64, 3.1%, P¼ 0.001,
OR: 11.429, 95% CI: 2.245–58.168).3
In addition, dialysis patients often need aspirin for
cardiovascular disease or NSAIDs for arthralgia.3,4 In
Sugimoto et al.’s study, the condition of aspirin/NSAIDs
usage is lacking; therefore, the conclusion may be misleading
when evaluating the incidence of peptic ulcer in dialysis
patients.1
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Helicobacter pylori play an
important role in the occurrence
of peptic ulcer in dialysis patients’
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We thank Dr Tseng et al. for their useful comments and
references about the effects of Helicobacter pylori eradica-
tion therapy and the role of non-steroidal anti-inflamma-
tory drugs (NSAIDs)/aspirin in dialysis patients.1
H. pylori eradication therapy is well known to decrease
peptic ulcer incidence and recurrence in long-term
follow-up studies in both dialysis patients and patients
with normal renal function. In our study, the prevalence
of peptic ulcer in H. pylori–positive and –negative
dialysis patients was 23.3 and 12.1%, respectively; most
peptic ulcers in uninfected patients were healing to the red
scar stage, and active ulcers were rare.2 However, the
recurrence rate of peptic ulcer was reported to be much
higher in dialysis patients (25%) than in non-dialysis
patients (3%) during two years’ observation.3 These data
suggest that gastroduodenal mucosal injury in dialysis
patients occurs frequently, irrespective of H. pylori
infection.
NSAIDs/aspirin intake, systemic/local circulatory fail-
ure, hypergastrinemia, high ammonia levels, and enhanced
inflammation were considered to be the causes of mucosal
injury in H. pylori–negative dialysis patients.2 Dialysis
patients frequently receive NSAIDs/aspirin for preventing
cardiovascular diseases, and NSAIDs/aspirin should play
important roles for preventing the development of peptic
ulcer.4 In our unpublished data, most cases receiving
NSAIDs/aspirin were able to prevent active ulcer develop-
ment by acid inhibitory drugs (that is, proton pump
inhibitor and/or histamine receptor antagonist). Overall,
we recommend that both H. pylori–positive and –negative
dialysis patients receive frequent endoscopic checkups and
anti-acid drugs, especially those with a history of peptic
ulcer, hemorrhage, and use of anticoagulants and NSAIDs/
aspirin.
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Is standard GLA gene mutation
analysis definitive for the
diagnosis of Fabry disease?
Kidney International (2009) 75, 1115–1116; doi:10.1038/ki.2009.28
To the Editor: In their recent publication, Fervenza et al.1
outlined the relevance of a correct diagnosis of Fabry disease
for understanding an atypical phenotype in a male patient,
emphasizing that, once the correct diagnosis was suspected
during renal biopsy, they performed molecular analyses in
order to confirm the diagnosis due to the uncommon renal
presentation.
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